ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1448 • 2012 ACR/ARHP Annual Meeting

    Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice

    Kunihiro Ichinose1, Atsushi Kawakami2 and George C. Tsokos3, 1Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA

    Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice. Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease associated with abnormal…
  • Abstract Number: 1449 • 2012 ACR/ARHP Annual Meeting

    Numbers of Splenic Long-Lived Plasma Cells in Autoimmune and Pre-Autoimmune Lupus Mice Are Linked to a Hyper-Responsive Variant of the Thrombopoietin Receptor and Enhanced Megakaryopoiesis

    Oliver Winter1, Katrin Moser2, Rudolf A. Manz3 and Falk Hiepe4, 1Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 2German Arthritis Research Center (DRFZ Berlin), Berlin, Germany, 3Institute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany, 4Med. Klinik m. Sp. Rheumatologie und klin. Immunologie, Charité University Hospital Berlin, Berlin, Germany

    Background/Purpose: Autoantibodies contribute to the pathogenesis of the autoimmune disease Systemic Lupus Erythematosus (SLE) by stimulating the immune response. Further, deposits of immune complexes in…
  • Abstract Number: 1450 • 2012 ACR/ARHP Annual Meeting

    MEDI-551 Depletes a Majority of Murine B Cells and Reduces Serum Titers of Autoantibodies in the SLE1-huCD19 TG Mice

    Sandra Gallagher1, Yue Wang1, Isharat Yusuf1, Thomas McCaughtry1, Ronald Herbst2 and Laura Carter1, 1Respiratory, Inflammation and Autoimmune, MedImmune, Gaithersburg, MD, 2Respiration, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by chronic inflammation that can affect various organs.  Hyperactive B cells appear to be key drivers in SLE…
  • Abstract Number: 1451 • 2012 ACR/ARHP Annual Meeting

    Estrogen Receptor Alpha Deficiency Protects Against Cognitive Defects in Murine Lupus

    Melissa A. Cunningham1, Osama S. Naga2, Heather A. Boger3, Ann-Charlotte E. Granholm-Bentley3 and Gary S. Gilkeson4, 1Med/Rheumatology, MUSC, Charleston, SC, 2Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, 3Neuroscience, Medical University of SC, Charleston, SC, 4Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Up to 80% of SLE patients have cognitive defects or affective disorders. The mechanism of CNS injury responsible for cognitive impairment is unknown.  Anti-dsDNA…
  • Abstract Number: 1452 • 2012 ACR/ARHP Annual Meeting

    Inherent Strain-Based Differences in Qualitative CD4 T Cell Responses Determine Lupus Severity

    Kateryna Soloviova1, Maksym Puliaiev1 and Charles S. Via2, 1Pathology Department, Uniformed Services University of Health Sciences, Bethesda, MD, 2Pathology Rm B3-100, Uniformed Services University of Health Sciences, Bethesda, MD

    Background/Purpose: A lupus-like disease can be induced in B6D2F1 mice by the transfer of parental DBA/2 splenocytes (DBA->F1). Transfer of splenocytes from the other parent…
  • Abstract Number: 1453 • 2012 ACR/ARHP Annual Meeting

    Estrogen Receptor Alpha Impacts Th17 Expansion in Murine Lupus

    Melissa A. Cunningham1, Osama S. Naga2, Jackie G. Eudaly3 and Gary S. Gilkeson4, 1Med/Rheumatology, MUSC, Charleston, SC, 2Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, 3Med/Rheumatology, Medical University of SC, Charleston, SC, 4Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic lupus erythematosus is a disease that disproportionately affects females. The mechanisms underlying the female predominance in this disease are largely unknown. We previously…
  • Abstract Number: 1454 • 2012 ACR/ARHP Annual Meeting

    Characterization of Renal Mononuclear Phagocyte Populations in Murine SLE Nephritis

    Ranjit Sahu1, Ramalingam Bethunaickan2 and Anne Davidson1, 1Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, 2Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose: Macrophages and dendritic cells contribute to renal damage in chronic renal diseases including lupus nephritis. However owing to their multiple phenotypic and functional variations,…
  • Abstract Number: 1455 • 2012 ACR/ARHP Annual Meeting

    Mitochondrial Dysfunction in the Liver of Lupus-Prone MRL/Lpr Mice Prior to Disease Onset

    Zachary A. Oaks1, Tiffany Telarico2 and Andras Perl3, 1SUNY, Syracuse, NY, 2Medicine, SUNY Upstate Medical University, Syracuse, NY, 3Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Liver dysfunction, characterized by serum elevation of liver enzymes, is detectable in 20% of patients with systemic lupus erythematosus (SLE.)  Males had a higher…
  • Abstract Number: 1416 • 2012 ACR/ARHP Annual Meeting

    Tumor Necrosis Factor Alpha Is Associated with Mood Disorders in Patients with Systemic Lupus Erythematosus

    Mariana Postal1, Aline T. Lapa1, Nailu A. Sinicato1, Karina Peliçari1, Lilian Costallat2 and Simone Appenzeller3, 1Medicine, State University of Campinas, Campinas, Brazil, 2Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil, 3Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil

    Background/Purpose: Elevated serum levels of tumor necrosis factor alpha (TNF-α) have been reported in patients with major depressive disorder and in patients with depression in…
  • Abstract Number: 1417 • 2012 ACR/ARHP Annual Meeting

    Favorable Response to Belimumab At Three Months

    Katrina M. Shum1, Jill P. Buyon2, H. Michael Belmont1, Andrew G. Franks Jr.3, Richard Furie4, Diane L. Kamen5, Susan Manzi6, Michelle Petri7, Rosalind Ramsey-Goldman8, Chung-E Tseng1, Ronald F. van Vollenhoven9, Daniel Wallace10 and Anca Askanase1, 1NYU School of Medicine, New York, NY, 2Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 3Dermatology & Medicine (Rheumatology), New York University, New York, NY, 4North Shore-LIJ Health System, Lake Success, NY, 5Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 6Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 9The Karolinska Institute, Stockholm, Sweden, 10Cedars-Sinai/UCLA, Los Angeles, CA

    Background/Purpose: Belimumab (Benlysta) is a monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the use…
  • Abstract Number: 1418 • 2012 ACR/ARHP Annual Meeting

    Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI

    Anca D. Askanase1, Katrina M. Shum1, Stan Kamp2, Fredonna C. Carthen2, Teresa J. Aberle3 and J.T. Merrill2, 1NYU School of Medicine, New York, NY, 2Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Disease activity measures used in SLE clinical studies, including the SLEDAI (SLE Disease Activity Index) and BILAG (British Isles Lupus Assessment Group) index are…
  • Abstract Number: 1419 • 2012 ACR/ARHP Annual Meeting

    Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up

    Renata Baronaite Hansen1 and Søren Jacobsen2, 1Department of Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, 2Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of developing coronary heart disease as well as infections. Acute infections have been recognized…
  • Abstract Number: 1420 • 2012 ACR/ARHP Annual Meeting

    Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus

    A. Lois-Iglesias1, J. Ishorari2 and D.A. Isenberg2, 1Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain. University College London, London, United Kingdom, 2Centre for Rheumatology, University College London, London, United Kingdom

    Background/Purpose:The aim of this study was to determine if there is any relation between ethnicity and outcome in  patients with SLE treated with B cell…
  • Abstract Number: 1421 • 2012 ACR/ARHP Annual Meeting

    Antimalarials Protect Systemic Lupus Erythematosus Patients From Damage Accrual During the First Five Years of the Disease

    Ioana Ruiz-Arruza1, D. D. Gladman1, Dominique Ibanez2 and Murray B. Urowitz2, 1Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Studies in the last 20 years have demonstrated that antimalarials (AM) prevent flares, protect from damage accrual, reduce the risk of thrombosis and increase…
  • Abstract Number: 1422 • 2012 ACR/ARHP Annual Meeting

    Clinical Associations of Anti-Smith Antibodies in Profile: A Multiethnic Lupus Cohort

    Yesenia C. Santiago-Casas1, Luis M. Vila1, Gerald McGwin Jr.2, Ryan S. Cantor2, Michelle Petri3, Rosalind Ramsey-Goldman4, John D. Reveille5, Robert P. Kimberly6, Graciela S. Alarcon7 and Elizabeth E. Brown8, 1Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, 2Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, 6Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 7Medicine, University of Alabama at Birmingham, Birmingham, AL, 8University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Anti-Smith (anti-Sm) antibodies are highly specific for systemic lupus erythematosus (SLE) and have an important value in the diagnosis of this disease.  However, whether…
  • « Previous Page
  • 1
  • …
  • 2504
  • 2505
  • 2506
  • 2507
  • 2508
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology